Advanced search
Publication Cover
Modern Rheumatology Case Reports Volume 5, 2021 - Issue 2
Journal homepage
102
Views
2
CrossRef citations to date
0
Altmetric
Case Reports

A case of polyangiitis overlap syndrome of giant cell arteritis and granulomatosis with polyangiitis successfully treated with rituximab

Akiko ShibataDepartment of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
,
Tsuneo KondoDepartment of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
,
Takahiko KurasawaDepartment of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
,
Kentaro ChinoDepartment of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
,
Yusuke OkadaDepartment of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
&
Koichi AmanoDepartment of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, JapanCorrespondence[email protected]
Pages 317-321 | Received 18 Mar 2020, Accepted 01 Jun 2020, Published online: 30 Nov 2020

References

  • Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.:
  • Leavitt RY, Fauci AS. Polyangiitis overlap syndrome. Classification and prospective clinical experience. Am J Med. 1986;81(1):79–85.
  • Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–1128.
  • Watts R, Lane S, Hauser T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–227.:
  • Amato MB, Barbas CS, Delmonte VC, et al. Concurrent Churg-Strauss syndrome and temporal arteritis in a young patient with pulmonary nodules. Am Rev Respir Dis. 1989;139(6):1539–1542.
  • Small P, Brisson ML. Wegener's granulomatosis presenting as temporal arteritis. Arthritis Rheum. 1991;34(2):220–223.
  • Nishino H, DeRemee RA, Rubino FA, et al. Wegener’s granulomatosis associated with vasculitis of the temporal artery: report of five cases. Mayo Clin Proc. 1993;68(2):115–121.
  • Zenone T, Souquet PJ, Bohas C, et al. Unusual manifestations of giant cell arteritis: pulmonary nodules, cough, conjunctivitis and otitis with deafness. Eur Respir J. 1994;7(12):2252–2254.
  • Tone SO, Godra A, Ing E. Polyangiitis overlap syndrome with granulomatosis with polyangiitis (Wegener's) and giant cell arteritis. Can J Ophthalmol. 2013;48(1):e6–e8.
  • Zuckerman R, Patel M, Alpert DR. A tale of two vasculitides: biopsy-proven giant cell arteritis followed by the independent development of renal-limited microscopic polyangiitis. BMJ Case Rep. 2017. doi:10.1136/bcr-2017-219228
  • Mader R, Narendran A, Lewtas J, et al. Systemic vasculitis following influenza vaccination – report of 3 cases and literature review. J Rheumatol. 1993;20(8):1429–1431.
  • Kelsall JT, Chalmers A, Sherlock CH, et al. Microscopic polyangiitis after influenza vaccination. J Rheumatol. 1997;24(6):1198–1202.
  • Uji M, Matsushita H, Iwata S. Microscopic polyangiitis after influenza vaccination. Intern Med. 2005;44(8):892–896.
  • Perez C, Loza E, Tinture T. Giant cell arteritis after influenza vaccination. Arch Intern Med. 2000;160(17):2677
  • Konishi M, Koarada S, Yamaguchi K, et al. [Case of microscopic polyangiitis and giant cell arteritis after influenza vaccination]. Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(3):154–161.
  • Cavazza A, Muratore F, Boiardi L, et al. Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations. Am J Surg Pathol. 2014;38(10):1360–1370.
  • Watelet B, Samson M, de Boysson H, et al. Treatment of giant-cell arteritis, a literature review. Mod Rheumatol. 2017;27(5):747–754.
  • Chen M, Kallenberg CG. ANCA-associated vasculitides-advances in pathogenesis and treatment. Nat Rev Rheumatol. 2010;6(11):653–664.
  • Quartuccio L, Maset M, De Maglio G, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford)). 2012;51(9):1677–1686.:
  • de Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43(1):105–112.
  • Gómez-Puerta JA, Quintana LF, Stone JH, et al. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev. 2012;11(9):646–652.
  • Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976–985.
  • Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328.
  • Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348–354.
  • Salvarani C, Hatemi G. Management of large-vessel vasculitis. Curr Opin Rheumatol. 2019;31(1):25–31.
  • Mayrbaeurl B, Hinterreiter M, Burgstaller S, et al. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin Rheumatol. 2007;26(9):1597–1598.
  • Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005;64(7):1099–1100.
  • Samson M, Corbera-Bellalta M, Audia S, et al. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev. 2017;16(8):833–844.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.